Stay updated on AFM24/SNK01 Combo in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24/SNK01 Combo in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24/SNK01 Combo in EGFR+ Cancers Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page shows a minor revision update: Revision: v3.3.2 has replaced Revision: v3.3.1. This update appears to be metadata/document control; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedThe page's revision line updated from Revision: v3.2.0 to Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedRemoved the government funding lapse notice, an operational banner about potential delays in updating information. This change does not affect the study details, eligibility criteria, or results.SummaryDifference0.3%

- Check43 days agoChange DetectedThe study record now shows a Terminated status with a note that Affimed and NKGen have mutually decided to discontinue the study. The notice describes pursuing alternative NK cell approaches by Affimed and NKGen's focus on CNS with SNK01.SummaryDifference0.4%

- Check71 days agoChange DetectedMajor update adds a government-operating-status notice and version bump to v3.2.0; a specific resource title was removed (v3.1.0).SummaryDifference4%

- Check79 days agoChange DetectedUpdated terminology to more specific phrasing and bumped version from v3.0.2 to v3.1.0.SummaryDifference0.6%

Stay in the know with updates to AFM24/SNK01 Combo in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24/SNK01 Combo in EGFR+ Cancers Clinical Trial page.